Congress Program
08:00-09:00
Registration
09:00-09:05
Congress Opening & Welcome
Prof. Jacob Schachter, Sheba Medical Center, Israel | Prof. Dr. Dirk Schadendorf, University Hospital Essen, Germany
09:05-10:30
Session 1
Chair: Prof. Dr. Dirk Jäger, Germany
09:05-09:30
The future role of immunotherapy as a basic platform for the treatment of cancer
Dirk Jäger
National Center for Tumor Diseases (NCT) Heidelberg, Germany
09:30-09:55
Predicting response to immunotherapy
Pier Francesco Ferrucci
Gruppo Multimedica, Milan, Italy
09:55-10:20
Immunotherapy management in special patient population
Mario Mandalà
Papa Giovanni XXIII Hospital in Bergamo, Italy
10:20-10:30
Discussion / Q&A
10:30-11:00
Coffee Break, Poster Viewing and Visit the Exhibition
11:00-12:00
Session 2
Chair: Dr. Mario Mandalà, Italy
11:00-11:25
Current status on neoadjuvant therapy in skin cancers
Dirk Schadendorf
University Hospital Essen, Germany
11:25-11:50
Neoadjuvant therapy in other solid tumors
Dirk Schadendorf
University Hospital Essen, Germany
11:50-12:00
Discussion/Q&A
12:00-12:30
Panel Discussion
Moderators: Prof. Jacob Schachter, Sheba Medical Center, Israel | Prof. Dr. Dirk Schadendorf, University Hospital Essen, Germany
12:00-12:30
What is Needed to Overcome PD1 Resistance
Dirk Jäger
National Center for Tumor Diseases (NCT) Heidelberg, Germany
Pier Francesco Ferrucci
Gruppo Multimedica, Milan, Italy
Mario Mandalà
Papa Giovanni XXIII Hospital in Bergamo, Italy
12:30-13:30
Lunch Break, Poster Viewing and Visit the Exhibition
13:30-15:00
Session 3
Chair: Prof. Jacob Schachter, Israel
13:30-13:55
Peptid-based and T-cell Therapy of cancer
Jens Bauer
University of Tübingen, Germany
13:55-14:20
T-cell directed therapies in advance melanoma
Jessica C. Hassel
University Hospital in Heidelberg, Germany
14:20-14:50
The concept of immunotherapy combinations - Supported by BMS
Jacob Schachter
Sheba Medical Center, Israel
14:50-15:00
Discussion/Q&A
15:00-15:30
Coffee Break, Poster Viewing and Visit the Exhibition
15:30-16:30
Session 4
15:30-16:30
Case Studies
Jacob Schachter
Sheba Medical Center, Israel
16:30
End of Day One
08:30-09:00
Registration
09:00-09:05
Congress Welcome - Day 2
Prof. Jacob Schachter, Sheba Medical Center, Israel | Prof. Dr. Dirk Schadendorf, University Hospital Essen, Germany
09:05-10:30
Session 5
Chair: Prof. Dr. Dirk Schadendorf, Germany
09:05-09:30
Immunotherapy in urogenital malignancies
Viktor Grünwald
University Hospital Essen, Germany
09:30-09:55
The Algorithm of the Treatment of Advanced Melanoma and Non-Melanoma Skin Cancer
Philippe Saiag
University of Versailles-SQY & University Paris-Saclay, France
09:55-10:20
Personalized Treatment of Immunotherapy Toxicity
Jessica C. Hassel
University Hospital in Heidelberg, Germany
10:20-10:30
Discussion / Q&A
10:30-11:00
Coffee Break, Poster Viewing and Visit the Exhibition
11:00-12:00
Session 6
Chair: Prof. Dr. Viktor Grünwald, Germany
11:00-11:25
Updates on immunotherapy of gynecological cancer
Ronnie Shapira-Frommer
Sheba Medical Center, Israel
11:25-11:50
Updates on the treatment of NSCLC & SCLC
Wilfried Eberhardt
University Hospital Essen, Germany
11:50-12:00
Discussion / Q&A
12:00-12:30
Panel Discussion
Moderators: Prof. Jacob Schachter, Sheba Medical Center, Israel | Prof. Dr. Dirk Schadendorf, University Hospital Essen, Germany
12:00-12:30
Combination with Checkpoint Inhibition. Rationales and Open Questions
Jessica C. Hassel
University Hospital in Heidelberg, Germany
Jens Bauer
University of Tübingen, Germany
Viktor Grünwald
University Hospital Essen, Germany
Ronnie Shapira-Frommer
Sheba Medical Center, Israel
12:30-13:30
Lunch Break, Poster Viewing and Visit the Exhibition
13:30-14:00
Special Lecture
13:30-14:00
Oncology Care in 2030
Jacob Schachter
Sheba Medical Center, Israel
14:00-15:10
Oral Presentations of Selected Abstracts
14:00-14:10
Pre-existing T-cell immunity and TCR Vβ Repertoire as Predictive Biomarkers for Immunotherapy in NSCLC Patients
14:10-14:20
Pre-planned interim results of a Phase 1B clinical trial of pembrolizumab (P) and dendritic cell vaccine (DC) in advanced pleural and peritoneal mesothelioma (M) patients
14:20-14:30
Next Generation CD44v6-Specific CAR-NK Cells Effective Against Solid Tumors
14:30-14:40
Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response
14:40-14:50
Probing Novel Tumor-associated Antigen Presentation Inhibitors for Immunotherapy of Cancer
14:50-15:00
Outcomes Of Immune-related Adverse Events In Patients Requiring Hospitalization In A Single UK Cancer Centre
15:00-15:10
Immunotherapy Related Pneumonitis: 5 Cases
15:10-15:40
Coffee Break, Poster Viewing and Visit the Exhibition
15:40-16:20
Session 7
Chair: Prof. Jacob Schachter, Israel
15:40-16:10
PD1 and Injectables – How to make a tumor hot
Dirk Schadendorf
University Hospital Essen, Germany
16:10-16:20
Congress Closing Remarks
Dirk Schadendorf
University Hospital Essen, Germany
Jacob Schachter
Sheba Medical Center, Israel
16:20
End of Congress
